Roche has licensed exclusive worldwide development and commercialisation rights to Galaxy Biotech's antibodies targeting fibroblast growth factor 2 (FGF2) for the treatment of cancer.
Roche's Dr Klaus Bosslet, head of discovery oncology, told Scrip that the FGF2 programme "complements its in-house portfolio" and will...